FRANK MORGAN C. 4

What Happened Frank Morgan, CEO of SANUWAVE Health, received an award/grant of 5,524 shares on 2026-06-30. The Form 4 lists the acquisition price as $0.00 (derivative award), indicating this was a compensation grant rather than an open‑market purchase or sale. A filing footnote states the related options were fully vested at the grant date.

Key Details

• Transaction date: 2026-06-30; Filing date: 2026-07-02 (timely filing).
• Transaction type/code: Award/Grant (A); 5,524 shares acquired at $0.00 per share.
• Total cash paid: $0.00 (compensatory award/derivative).
• Shares owned after transaction: not specified in the public Form 4 filing.
• Footnote: F1 — options were fully vested at the grant date.
• No indication of a 10b5-1 plan, tax withholding, or sale in this filing.

Context This was a compensation award/derivative transaction (not an outright purchase or sale). The footnote that options were fully vested at grant means the award was immediately vested at grant date. Compensation grants are common for executives and are not direct market-price indicators like an open‑market purchase or sale.